AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32651892 — intervention group
Group type: EXPERIMENTAL
Intervention: AG genotype carriers in women
Number of subjects: 2022
Study 32651892 — intervention group
Group type: EXPERIMENTAL
Intervention: GG genotype carriers in men
Number of subjects: 2022
Study 32651892 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of the rs2175898 G allele
Number of subjects: 2022
Study 32651892 — intervention group
Group type: EXPERIMENTAL
Intervention: AG+GG/AG genotype in men
Number of subjects: 2022
Study 32651892 — intervention group
Group type: COMPARATOR
Intervention: AG genotype in women and GG genotype in men
Number of subjects: 2022
Study 35829980 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model A based on T2WI and ADC images
Number of subjects: 133
Study 33675347 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal iron supplementation (60 mg elemental iron as ferrous fumarate daily from 13-23 weeks of gestation until 1 month postpartum)
Number of subjects: 470
Study 33675347 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal iron supplementation
Number of subjects: 470
Study 32273169 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal ovarian cancer screening using a longitudinal CA125 algorithm
Number of subjects: 0
Study 32273169 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended follow up in the UKCTOCS trial
Number of subjects: 0
Study 32273169 — intervention group
Group type: COMPARATOR
Intervention: Surveillance of high risk women
Number of subjects: 0
Study 35792881 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-tablet default
Number of subjects: 6309
Study 35792881 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-tablet default
Number of subjects: 6309
Study 35792881 — intervention group
Group type: COMPARATOR
Intervention: Control (no change)
Number of subjects: 6309
Study 34031220 — intervention group
Group type: EXPERIMENTAL
Intervention: Basivertebral nerve (BVN) ablation
Number of subjects: 140
Study 34031220 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 140
Study 32259823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nascum®‐Plus (NP)
Number of subjects: 18
Study 32259823 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study 35667420 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with intrauterine instillation of hyaluronic acid gel
Number of subjects: 343
Study 35667420 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 343
Study 33789284 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Number of subjects: 157
Study 33789284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 35748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea salt‐lemon essence Closeup natural smile
Number of subjects: 27
Study 35748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal Complete 8 Charcoal
Number of subjects: 27
Study 35748445 — intervention group
Group type: COMPARATOR
Intervention: Signal Complete 8 Original (control)
Number of subjects: 27
Study 33557254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy based on the Comprehensive Cognitive Activation Program in Dementia for 8 months, with weekly sessions of 45 min
Number of subjects: 334
Study 33557254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy
Number of subjects: 334
Study 32539076 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MHCK7.micro-dystrophin, single dose of 2.0 × 10^14 vg/kg infused through a peripheral limb vein, daily prednisolone 1 mg/kg starting 1 day before gene delivery (30-day taper after infusion)
Number of subjects: 4
Study 34245777 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (4 × 4‐min of high‐intensity work periods at 85%–95% peak heart rate)
Number of subjects: 135
Study 34245777 — intervention group
Group type: EXPERIMENTAL
Intervention: NW (resting HR + 20–40 bpm)
Number of subjects: 135
Study 34245777 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT (resting HR + 20–40 bpm)
Number of subjects: 135
Study 34245777 — intervention group
Group type: COMPARATOR
Intervention: All groups (HIIT, NW, MICT)
Number of subjects: 135
Study 34570596 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine live (ZVL)
Number of subjects: 617
Study 34570596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study 36382358 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-514 200 mg
Number of subjects: 24
Study 36382358 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-514 400 mg
Number of subjects: 24
Study 36382358 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-514 800 mg
Number of subjects: 24
Study 36382358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34338114 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol-based multivitamin supplement
Number of subjects: 101
Study 34338114 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 101
Study 34843669 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised regimen (25 mg/kg loading dose, followed by 15 mg/kg every 12 h or 8 h for 5 ± 1 days)
Number of subjects: 242
Study 34843669 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (no loading dose; 15 mg/kg every 24 h, 12 h, or 8 h for 10 ± 2 days)
Number of subjects: 242
Study 34843669 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised regimen
Number of subjects: 242
Study 34843669 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 242
Study 33593795 — intervention group
Group type: EXPERIMENTAL
Intervention: c-LRTI-VAS (COPD-Lower Respiratory Tract Infection Visual Analogue Score)
Number of subjects: 190
Study 33593795 — intervention group
Group type: EXPERIMENTAL
Intervention: c-LRTI-VAS
Number of subjects: 190
Study 32349692 — intervention group
Group type: EXPERIMENTAL
Intervention: Online guided self-help Cognitive Behavioral Therapy-Enhanced intervention
Number of subjects: 180
Study 32349692 — intervention group
Group type: COMPARATOR
Intervention: Control waiting list condition
Number of subjects: 180
Study 35354636 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention comprising self-management of disabilities, economic empowerment, and psychosocial support.
Number of subjects: 630
Study 35354636 — intervention group
Group type: COMPARATOR
Intervention: Usual practice and care (control group).
Number of subjects: 630
Study 32114899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 min)
Number of subjects: 30
Study 32114899 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (2 mA for 30 s)
Number of subjects: 30
Study 32362229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering (target SBP <120 mm Hg)
Number of subjects: 8022
Study 32362229 — intervention group
Group type: COMPARATOR
Intervention: Standard BP lowering (target SBP <140 mm Hg)
Number of subjects: 8022
Study 32362229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP lowering
Number of subjects: 8022
Study 35320161 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) administered at the same rate as lidocaine
Number of subjects: 90
Study 34306189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care
Number of subjects: 214
Study 34306189 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care alone
Number of subjects: 214
Study 35294397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesomet (0.5 mg tesofensine/50 mg)
Number of subjects: 21
Study 35294397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 33032712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 892
Study 33032712 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 892
Study 35902780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasty School model (intervention)
Number of subjects: 130
Study 35902780 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 32168178 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body (TB) resistance training
Number of subjects: 21
Study 32168178 — intervention group
Group type: COMPARATOR
Intervention: Split Routine (SR) resistance training
Number of subjects: 21
Study 36260302 — intervention group
Group type: EXPERIMENTAL
Intervention: cCDT (alteplase, 0.5 mg/catheter/h for 24 hours) plus heparin
Number of subjects: 94
Study 36260302 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation monotherapy
Number of subjects: 94
Study 35114778 — intervention group
Group type: COMPARATOR
Intervention: LAA stroke group
Number of subjects: 353
Study 35114778 — intervention group
Group type: COMPARATOR
Intervention: cerebral SVD stroke group
Number of subjects: 353
Study 35774483 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (1.5 mA, 20 min)
Number of subjects: 40
Study 35774483 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 35170457 — intervention group
Group type: EXPERIMENTAL
Intervention: Community sensitization through community meetings, wall paintings, and distribution of pamphlets
Number of subjects: 79
Study 32861428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral pharmacological agents for spasticity management
Number of subjects: 0
Study 35432560 — intervention group
Group type: EXPERIMENTAL
Intervention: Jie Yu Wan (JYW) high dose (24 g/day)
Number of subjects: 133
Study 35432560 — intervention group
Group type: COMPARATOR
Intervention: Buspirone high dose (30 mg/day)
Number of subjects: 133
Study 35432560 — intervention group
Group type: EXPERIMENTAL
Intervention: Jie Yu Wan (JYW) low dose (12 g/day)
Number of subjects: 133
Study 35432560 — intervention group
Group type: COMPARATOR
Intervention: Buspirone low dose (15 mg/day)
Number of subjects: 133
Study 33508955 — intervention group
Group type: EXPERIMENTAL
Intervention: Home training
Number of subjects: 80
Study 33508955 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 80
Study 33508955 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 32847570 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 32
Study 32847570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33685418 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (1.5 days + 2 booster sessions of 180 min each at 3 and 6 months)
Number of subjects: 200
Study 33685418 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 200
Study 32894811 — intervention group
Group type: EXPERIMENTAL
Intervention: Covid‐19 diagnosis and its effect on kidney function
Number of subjects: 96
Study 32894811 — intervention group
Group type: EXPERIMENTAL
Intervention: Covid‐19 diagnosis
Number of subjects: 96
Study 32894811 — intervention group
Group type: EXPERIMENTAL
Intervention: Covid‐19 diagnosis in severe pneumonia group
Number of subjects: 96
Study 32894811 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory findings in ARDS group
Number of subjects: 96
Study 33034707 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of olive leaf extract (OLE) for 8 weeks
Number of subjects: 77
Study 33034707 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 77
Study 32217429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (25 mg, 50 mg, 75 mg)
Number of subjects: 1105
Study 35698072 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned lactation education program (two sessions in the hospital and three 20-minute sessions in health centers)
Number of subjects: 80
Study 35698072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lactation education program)
Number of subjects: 80
Study 33987696 — intervention group
Group type: EXPERIMENTAL
Intervention: Light angle at 60°
Number of subjects: 51
Study 33987696 — intervention group
Group type: COMPARATOR
Intervention: Light angle at 30°
Number of subjects: 51
Study 33987696 — intervention group
Group type: COMPARATOR
Intervention: Light angle at 0°
Number of subjects: 51
Study 33987696 — intervention group
Group type: EXPERIMENTAL
Intervention: Light angle at 30° and 60°
Number of subjects: 51
Study 34850180 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injections
Number of subjects: 26
Study 34850180 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 26
Study 32551876 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment style
Number of subjects: 200
Study 32551876 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety-avoidance styles
Number of subjects: 200
Study 35599775 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveCBT (30 min of moderate intensity exercise before CBT sessions)
Number of subjects: 10
Study 35599775 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveCBT
Number of subjects: 10
Study 35599775 — intervention group
Group type: COMPARATOR
Intervention: CalmCBT (30 min of usual activities before CBT sessions)
Number of subjects: 10
Study 32441856 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent heart failure hospitalization
Number of subjects: 3988
Study 33096517 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 60
Study 33096517 — intervention group
Group type: COMPARATOR
Intervention: Control (sham subcutaneous infiltration)
Number of subjects: 60
Study 33021598 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried Amniotic Membrane (AM)
Number of subjects: 35
Study 33021598 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum gauze (control)
Number of subjects: 35
Study 36057376 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice architecture intervention to nudge clinicians toward non-opioid treatments for opioid-naïve patients.
Number of subjects: 43
Study 36057376 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of the prescription drug monitoring program (PDMP) within the EHR.
Number of subjects: 43
Study 33666270 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplements (3.2 × 10^9 CFU per day for 12 weeks)
Number of subjects: 76
Study 33666270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (empty capsules filled with starch)
Number of subjects: 76
Study 35675898 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression of the fourth ventricle (CV4) technique
Number of subjects: 40
Study 35675898 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral technique (ST)
Number of subjects: 40
Study 35675898 — intervention group
Group type: COMPARATOR
Intervention: Sham compression of the fourth ventricle (sCV4)
Number of subjects: 40
Study 35675898 — intervention group
Group type: COMPARATOR
Intervention: Sham sacral technique (sST)
Number of subjects: 40
Study 32452923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 120
Study 32452923 — intervention group
Group type: COMPARATOR
Intervention: Control (instant warm compresses + MGX)
Number of subjects: 120
Study 32618395 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face group positive psychotherapy (PPC)
Number of subjects: 269
Study 32618395 — intervention group
Group type: COMPARATOR
Intervention: Online group positive psychotherapy (OPPC)
Number of subjects: 269
Study 35285277 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6766
Number of subjects: 0
Study 35285277 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-6766 plus defactinib
Number of subjects: 0
Study 33789572 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual attire
Number of subjects: 632
Study 33789572 — intervention group
Group type: COMPARATOR
Intervention: White coat
Number of subjects: 632
Study 32642839 — intervention group
Group type: COMPARATOR
Intervention: Quadratus lumborum block (QLB)
Number of subjects: 7
Study 36112778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gimsilumab (anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody)
Number of subjects: 0
Study 36112778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33962258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal Vibration A (20 Hz, 3 mm)
Number of subjects: 15
Study 33962258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal Vibration B (20 Hz, 5 mm)
Number of subjects: 15
Study 33962258 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibrations)
Number of subjects: 15
Study 33218878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (OCH)-rich drink
Number of subjects: 95
Study 33218878 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dextrose 10% infusion
Number of subjects: 95
Study 33218878 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study 32278771 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal 0.5 mg ranibizumab
Number of subjects: 40
Study 32278771 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal 0.5 mg ranibizumab plus TRP
Number of subjects: 40
Study 32278771 — intervention group
Group type: COMPARATOR
Intervention: 3 monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP
Number of subjects: 40
Study 37353143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular volume (VV) estimation
Number of subjects: 59
Study 37353143 — intervention group
Group type: EXPERIMENTAL
Intervention: VP shunt insertion
Number of subjects: 59
Study 37353143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 59
Study 37353143 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum ventricular index and anterior horn width
Number of subjects: 59
Study 34397332 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB)
Number of subjects: 11
Study 32769639 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy-based intervention (n=129)
Number of subjects: 250
Study 32769639 — intervention group
Group type: COMPARATOR
Intervention: Time-matched control group (n=121)
Number of subjects: 250
Study 34254567 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxoplasma gondii infection (seroprevalence)
Number of subjects: 415
Study 34254567 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-T. gondii IgM positivity
Number of subjects: 415
Study 34254567 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-T. gondii IgG positivity
Number of subjects: 415
Study 34254567 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG plus IgM positivity
Number of subjects: 415
Study 34254567 — intervention group
Group type: EXPERIMENTAL
Intervention: Residence in rural communities
Number of subjects: 415
Study 34254567 — intervention group
Group type: EXPERIMENTAL
Intervention: Islam religion
Number of subjects: 415
Study 35078530 — intervention group
Group type: EXPERIMENTAL
Intervention: We Can Quit (WCQ) - a peer‐delivered community‐based stop‐smoking programme
Number of subjects: 0
Study 35078530 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care by the Irish Health Service Executive (HSE)
Number of subjects: 0
Study 32122863 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging acupuncture treatment after stroke
Number of subjects: 30
Study 32122863 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture method
Number of subjects: 30
Study 34024812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glide (SNAG)
Number of subjects: 64
Study 34024812 — intervention group
Group type: COMPARATOR
Intervention: Sham SNAG
Number of subjects: 64
Study 32596297 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT) for 3 years
Number of subjects: 36
Study 35981565 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivipansel
Number of subjects: 345
Study 35981565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 33982388 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme based on an attitude-social influence-self-efficacy model
Number of subjects: 60
Study 33982388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 32245197 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (0.33 g·kg−1·d−1 protein)
Number of subjects: 16
Study 32245197 — intervention group
Group type: COMPARATOR
Intervention: Control (isonitrogenous control, 0.33 g·kg−1·d−1 protein)
Number of subjects: 16
Study 33744331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl with Ketamine
Number of subjects: 60
Study 33744331 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine
Number of subjects: 60
Study 32912091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP) workshops
Number of subjects: 241
Study 32698326 — intervention group
Group type: EXPERIMENTAL
Intervention: Filipino version of the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 131
Study 33879535 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of covarying grey matter (GM) volumes using spatial independent component analysis (ICA)
Number of subjects: 988
Study 33879535 — intervention group
Group type: EXPERIMENTAL
Intervention: ICA measures
Number of subjects: 988
Study 33285602 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (1.4 mg elemental Zn/kg/d orally for 10 days)
Number of subjects: 180
Study 32936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels (25-hydroxyvitamin D) in men
Number of subjects: 530
Study 32936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels (25-hydroxyvitamin D) in women
Number of subjects: 530
Study 32936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue measured with ESAS in men
Number of subjects: 530
Study 32936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue measured with ESAS in women
Number of subjects: 530
Study 32089329 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple fixed combination (TFC) of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution
Number of subjects: 185
Study 32089329 — intervention group
Group type: COMPARATOR
Intervention: Dual fixed combination (DFC) of brimonidine 0.2%/timolol 0.5%
Number of subjects: 185
Study 34487415 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent overlap
Number of subjects: 5605